232 related articles for article (PubMed ID: 34110453)
1. T cells, particularly activated CD4
Wang Z; Chimenti MS; Strouse C; Weiner GJ
Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity.
Wang Z; Yin C; Lum LG; Simons A; Weiner GJ
J Hematol Oncol; 2021 Dec; 14(1):204. PubMed ID: 34886888
[TBL] [Abstract][Full Text] [Related]
3. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
[TBL] [Abstract][Full Text] [Related]
4. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
5. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
7. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
8. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
9. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.
Rudnicka D; Oszmiana A; Finch DK; Strickland I; Schofield DJ; Lowe DC; Sleeman MA; Davis DM
Blood; 2013 Jun; 121(23):4694-702. PubMed ID: 23613524
[TBL] [Abstract][Full Text] [Related]
10. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
Wang Z; Weiner GJ
J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
[TBL] [Abstract][Full Text] [Related]
13. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
[TBL] [Abstract][Full Text] [Related]
14. Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
Hassenrück F; Knödgen E; Göckeritz E; Midda SH; Vondey V; Neumann L; Herter S; Klein C; Hallek M; Krause G
Biomed Res Int; 2018; 2018():1023490. PubMed ID: 29750146
[TBL] [Abstract][Full Text] [Related]
15. Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells
Niu C; Chen Y; Li M; Zhu S; Zhou L; Xu D; Li Z; Xu J; Li W; Wang Y; Cui J
Front Immunol; 2021; 12():658562. PubMed ID: 34113342
[TBL] [Abstract][Full Text] [Related]
16. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
17. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
18. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
Front Immunol; 2021; 12():641521. PubMed ID: 33796107
[TBL] [Abstract][Full Text] [Related]
19. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.
Loubeau M; Ahmad A; Toma E; Menezes J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):137-45. PubMed ID: 9390564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
